Dr. Robert Huizinga reports

KANE BIOTECH EXPANDS U.S. COMMERCIAL FOOTPRINT WITH STRATEGIC DISTRIBUTION PARTNERSHIP

Kane Biotech Inc. has made two significant expansions to its U.S. commercialization strategy as it prepares for nationwide growth of its advanced wound care portfolio, including the revyve anti-microbial wound gel. These strategic steps include the signing of a federally aligned distribution partnership to support entry into the U.S. Veterans Affairs (VA) market, the U.S. Department of Defense (DOD) and U.S. Indian Health Services (IHS) and the signing of multiple independent sales representative agreements.

U.S. FDA 510(k) cleared and Health Canada approved revyve anti-microbial wound gel and revyve anti-microbial wound gel spray

Kane Biotech has signed a distribution agreement with Marathon Medical Corp., a federally verified service-disabled veteran-owned small business (SDVOSB) and a leading nationwide medical supply distributor. Marathon provides premium medical, surgical and wound care products through an extensive portfolio of federal procurement contracts, positioning the company as a key partner within the VA, DOD and IHS health care supply chain.

By partnering with Marathon, Kane gains access to established U.S. government-authorized purchasing pathways, significantly streamlining procurement, logistics and product onboarding for the revyve wound care line.

Kane has commenced building a contract-based sales team with team members in place across the U.S. It will continue to build this group throughout 2026.

"We are continuing to strategically build the commercial infrastructure required to make revyve a national brand in advanced wound care," said interim chief executive officer, Dr. Robert Huizinga. "Our new contract-based sales agents expand our reach into key markets, while our partnership with Marathon Medical, gives us a powerful foothold within the U.S. government system -- an essential step in making revyve accessible to the veterans, active service members and indigenous peoples."

About Kane Biotech Inc.

Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve anti-microbial wound gel, revyve anti-microbial wound gel spray, and revyve anti-microbial skin and wound cleanser are all U.S. FDA 510(k) cleared. revyve anti-microbial wound gel and revyve anti-microbial wound gel spray are also Health Canada approved.

We seek Safe Harbor.